Novartis expands gene-editing program | November 20, 2017 Issue - Vol. 95 Issue 46 | Chemical & Engineering News
Volume 95 Issue 46 | p. 13 | Concentrates
Issue Date: November 20, 2017

Novartis expands gene-editing program

Department: Business
Keywords: Biotechnology, Novartis, Homology Medicines, AAV, gene therapy, gene editing

A collaboration with Bedford, Mass.-based Homology Medicines will expand gene-editing research at Novartis. Homology’s gene-editing technique relies on recently discovered variants of adeno-associated viruses rather than on CRISPR. AAVs induce homologous recombination in a cell’s genome to swap out an old piece of DNA for a new one. The goal is to treat genetic blood and eye diseases. The financial terms are not disclosed, but Novartis previously invested in Homology as part of the firm’s $83.5 million series B funding.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment